SCIENCE & INVESTIGATION AGAINST CANCER

OUR SCIENCE: HIGHLIGHTS

Redefining cancer therapies

We are pioneering the future of cancer treatment through the use of oncolytic virotherapy - a groundbreaking approach that harnesses viruses to target and eliminate cancer cells.

Our core innovation revolves around using Avian Paramyxovirus (APMV)-based therapy. This innovative virotherapy effectively creates a personalized vaccine right at the tumor site, eliminating the need for complex processing or customization.

With our therapeutic approach is expected that viruses stimulate each patient's immune system to create its own unique vaccine tailored to its specific tumor. This process activates T cells against tumor neoantigens without the need for prior identification, a significant advancement over traditional immunotherapies.

Moreover, our APMV therapy has demonstrated the ability to elicit systemic, long-lasting anti-tumor responses in murine models, offering protection against cancer recurrence and metastasis.

By harnessing the power of the body's own immune system in this targeted manner, Virofend Therapeutics is opening new frontiers in cancer treatment, offering hope for more effective, personalized, and durable therapeutic outcomes.

ViroFend pipeline 2025

PROJECTS AND CALLS

Public funding and recognitions

Technical assistance in monitoring and analysis of the patent application status APMV AND USES THEREOF FOR THE TREATMENT OF CANCER

Funded by: ICECYL – R&D Project (co-financed by ERDF)

This R&D project aims to prepare the clinical transfer of an innovative oncolytic virotherapy platform for the treatment of colorectal cancer. The project focuses on consolidating and analyzing preclinical data, establishing the clinical batch production process under GMP conditions, regulatory validation, and full design of the Phase I/IIa clinical trial. As a result, it is expected to initiate the first human clinical trial and position Virofend Therapeutics as a pioneering company in Spain in transitioning oncolytic virus-based therapies from preclinical research to clinical practice.

Project co-financed by the Junta de Castilla y León, through the Institute for Business Competitiveness of Castilla y León (ICECYL), and the European Regional Development Fund (ERDF). A way to make Europe.

Design and development of an oncolytic virotherapy based on the recombinant virus VFT111 for sustained immunostimulation in colorectal cancer through an innovative specific replication platform

Funded by: ICECYL – SME Innovation (ERDF)

This business innovation project is aimed at enhancing the company's competitiveness through the development and consolidation of proprietary technologies in the field of oncolytic virotherapy. Its objectives include strengthening internal innovation processes and accelerating the application of research results toward market-oriented solutions. As an expected outcome, the project will contribute to reinforcing the company's innovative capacity and positioning it in the biotechnology sector.